KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Return on Capital Employed (2016 - 2025)

Rigel Pharmaceuticals has reported Return on Capital Employed over the past 15 years, most recently at 45.0% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 1763.0% year-over-year to 45.0%; the TTM value through Dec 2025 reached 45.0%, up 1763.0%, while the annual FY2025 figure was 52.38%, 2108.0% up from the prior year.
  • Return on Capital Employed for Q4 2025 was 45.0% at Rigel Pharmaceuticals, down from 91.34% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 99.87% in Q2 2025 and troughed at 106.05% in Q3 2022.
  • A 5-year average of 14.41% and a median of 12.06% in 2021 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: plummeted -9870bps in 2022 and later skyrocketed 11298bps in 2025.
  • Year by year, Return on Capital Employed stood at 11.02% in 2021, then plummeted by -744bps to 93.0% in 2022, then soared by 65bps to 32.52% in 2023, then soared by 184bps to 27.37% in 2024, then surged by 64bps to 45.0% in 2025.
  • Business Quant data shows Return on Capital Employed for RIGL at 45.0% in Q4 2025, 91.34% in Q3 2025, and 99.87% in Q2 2025.